Biological features of APL according to CD56 expression
| Characteristic . | CD56-positive, no. (%) . | CD56-negative, no. (%) . | P . |
|---|---|---|---|
| Overall | 72 (100) | 579 (100) | |
| Morphologic subtype (n = 645) | |||
| Hypergranular | 51 (72) | 461 (80) | .09 |
| Microgranular | 20 (28) | 113 (20) | |
| Cytogenetics (n = 476) | |||
| t(15;17) | 37 (74) | 307 (72) | .77 |
| t(15;17) plus other* | 13 (26) | 109 (28) | |
| FLT3-ITD mutations (n = 243) | |||
| Positive | 10 (31) | 54 (26) | .49 |
| Negative | 22 (69) | 157 (74) | |
| PML/RARα isoform (n = 576) | |||
| BCR1/BCR2 | 25 (38) | 308 (60) | < .001 |
| BCR3 | 40 (62) | 203 (40) | |
| CD2 (n = 538) | |||
| Positive | 25 (46) | 117 (24) | < .001 |
| Negative | 29 (54) | 367 (76) | |
| CD7 (n = 505) | |||
| Positive | 9 (18) | 22 (5) | < .001 |
| Negative | 40 (82) | 434 (95) | |
| CD9 (n = 189) | |||
| Positive | 11 (65) | 64 (37) | .06 |
| Negative | 6 (35) | 108 (63) | |
| CD11b (n = 464) | |||
| Positive | 8 (17) | 34 (8) | .07 |
| Negative | 38 (83) | 384 (92) | |
| CD15 (n = 555) | |||
| Positive | 26 (43) | 128 (26) | .004 |
| Negative | 34 (57) | 367 (74) | |
| CD34 (n = 607) | |||
| Positive | 30 (48) | 117 (21) | < .001 |
| Negative | 32 (52) | 428 (79) | |
| CD117 (n = 538) | |||
| Positive | 50 (88) | 357 (74) | .02 |
| Negative | 7 (12) | 124 (26) | |
| HLA-DR (n = 569) | |||
| Positive | 10 (18) | 28 (5) | .001 |
| Negative | 46 (82) | 485 (95) |
| Characteristic . | CD56-positive, no. (%) . | CD56-negative, no. (%) . | P . |
|---|---|---|---|
| Overall | 72 (100) | 579 (100) | |
| Morphologic subtype (n = 645) | |||
| Hypergranular | 51 (72) | 461 (80) | .09 |
| Microgranular | 20 (28) | 113 (20) | |
| Cytogenetics (n = 476) | |||
| t(15;17) | 37 (74) | 307 (72) | .77 |
| t(15;17) plus other* | 13 (26) | 109 (28) | |
| FLT3-ITD mutations (n = 243) | |||
| Positive | 10 (31) | 54 (26) | .49 |
| Negative | 22 (69) | 157 (74) | |
| PML/RARα isoform (n = 576) | |||
| BCR1/BCR2 | 25 (38) | 308 (60) | < .001 |
| BCR3 | 40 (62) | 203 (40) | |
| CD2 (n = 538) | |||
| Positive | 25 (46) | 117 (24) | < .001 |
| Negative | 29 (54) | 367 (76) | |
| CD7 (n = 505) | |||
| Positive | 9 (18) | 22 (5) | < .001 |
| Negative | 40 (82) | 434 (95) | |
| CD9 (n = 189) | |||
| Positive | 11 (65) | 64 (37) | .06 |
| Negative | 6 (35) | 108 (63) | |
| CD11b (n = 464) | |||
| Positive | 8 (17) | 34 (8) | .07 |
| Negative | 38 (83) | 384 (92) | |
| CD15 (n = 555) | |||
| Positive | 26 (43) | 128 (26) | .004 |
| Negative | 34 (57) | 367 (74) | |
| CD34 (n = 607) | |||
| Positive | 30 (48) | 117 (21) | < .001 |
| Negative | 32 (52) | 428 (79) | |
| CD117 (n = 538) | |||
| Positive | 50 (88) | 357 (74) | .02 |
| Negative | 7 (12) | 124 (26) | |
| HLA-DR (n = 569) | |||
| Positive | 10 (18) | 28 (5) | .001 |
| Negative | 46 (82) | 485 (95) |
Plus other additional chromosomal abnormalities.